The major therapies aimed at lowering lipid levels in the bloodstream all derive from the discovery of human mutants who exhibit low blood lipids and a lesser burden of atherosclerosis and cardiovascular mortality. The therapies aim at recapturing some of the effects of these mutations, which inevitably means that they confer smaller benefits than possessing the mutation over the full course of life. Over time these therapies have moved from small molecule drugs to the present approach of small interfering RNA to directly inhibit expression of specific genes. ANGPLT3 is the latest target, and here note the clinic…
ANGPTL3 Inhibition is the Newest Advance in Lipid-Lowering Therapies
The major therapies aimed at lowering lipid levels in the bloodstream all derive from the discovery of human mutants who exhibit low blood lipids and a lesser burden of atherosclerosis and cardiovascular mortality. The therapies aim at recapturing some of the effects of these mutations, which inevitably means that they confer smaller benefits than possessing the mutation over the full course of life. Over time these therapies have moved from small molecule drugs to the present approach of small interfering RNA to directly inhibit expression of specific genes. ANGPLT3 is the latest target, and here note the clinic…